The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

During immuno-mediated attack of the brain, activation of endocannabinoids represents a protective mechanism, aimed at reducing both neurodegenerative and inflammatory damage through various and partially converging mechanisms that involve neuronal and immune cells. Here, we review the main alterations of the endocannabinoid system (ECS) within the central nervous system and in peripheral blood mononuclear cells, in order to discuss the intriguing observation that elements of the peripheral ECS mirror central dysfunctions of endocannabinoid signaling. As a consequence, elements of blood ECS might serve as novel, non-invasive diagnostic tools of several neurological disorders, and targeting the ECS might be useful for therapeutic purposes. In addition, we discuss the appealing working hypothesis that the presence of type-1 cannabinoid receptors on the luminal side, and that of type-2 cannabinoid receptors on the abluminal side of the blood-brain barrier, could drive a unidirectional transport of AEA in the luminal → abluminal direction (i.e., from blood to brain), thus implying that blood may be a reservoir of AEA for the brain. On this basis, it can be expected that an unbalance of the endogenous tone of AEA in the blood may sustain a similar unbalance of its level within the brain, as demonstrated in Huntington's disease, Parkinson's disease, multiple sclerosis, attention-deficit/hyperactivity disorder, schizophrenia, depression and headache.

Original languageEnglish
Pages (from-to)2370-2382
Number of pages13
JournalCurrent Pharmaceutical Design
Volume14
Issue number23
DOIs
Publication statusPublished - Aug 2008

Fingerprint

Endocannabinoids
Lymphocytes
Cannabinoid Receptors
Brain
Huntington Disease
Attention Deficit Disorder with Hyperactivity
Nervous System Diseases
Blood-Brain Barrier
Multiple Sclerosis
Headache
Parkinson Disease
Blood Cells
Schizophrenia
Central Nervous System
Depression

Keywords

  • Blood-brain barrier
  • Cannabinoid receptors
  • Depression
  • Immune response
  • Lymphocytes
  • Metabolism
  • Migraine
  • Neurodegeneration
  • Neuroinflammation
  • Transport
  • Vanilloid receptor

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

@article{5a7d26b6f7284521831a0eab7d537e10,
title = "The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases",
abstract = "During immuno-mediated attack of the brain, activation of endocannabinoids represents a protective mechanism, aimed at reducing both neurodegenerative and inflammatory damage through various and partially converging mechanisms that involve neuronal and immune cells. Here, we review the main alterations of the endocannabinoid system (ECS) within the central nervous system and in peripheral blood mononuclear cells, in order to discuss the intriguing observation that elements of the peripheral ECS mirror central dysfunctions of endocannabinoid signaling. As a consequence, elements of blood ECS might serve as novel, non-invasive diagnostic tools of several neurological disorders, and targeting the ECS might be useful for therapeutic purposes. In addition, we discuss the appealing working hypothesis that the presence of type-1 cannabinoid receptors on the luminal side, and that of type-2 cannabinoid receptors on the abluminal side of the blood-brain barrier, could drive a unidirectional transport of AEA in the luminal → abluminal direction (i.e., from blood to brain), thus implying that blood may be a reservoir of AEA for the brain. On this basis, it can be expected that an unbalance of the endogenous tone of AEA in the blood may sustain a similar unbalance of its level within the brain, as demonstrated in Huntington's disease, Parkinson's disease, multiple sclerosis, attention-deficit/hyperactivity disorder, schizophrenia, depression and headache.",
keywords = "Blood-brain barrier, Cannabinoid receptors, Depression, Immune response, Lymphocytes, Metabolism, Migraine, Neurodegeneration, Neuroinflammation, Transport, Vanilloid receptor",
author = "Diego Centonze and Luca Battistini and Mauro Maccarrone",
year = "2008",
month = "8",
doi = "10.2174/138161208785740018",
language = "English",
volume = "14",
pages = "2370--2382",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "23",

}

TY - JOUR

T1 - The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases

AU - Centonze, Diego

AU - Battistini, Luca

AU - Maccarrone, Mauro

PY - 2008/8

Y1 - 2008/8

N2 - During immuno-mediated attack of the brain, activation of endocannabinoids represents a protective mechanism, aimed at reducing both neurodegenerative and inflammatory damage through various and partially converging mechanisms that involve neuronal and immune cells. Here, we review the main alterations of the endocannabinoid system (ECS) within the central nervous system and in peripheral blood mononuclear cells, in order to discuss the intriguing observation that elements of the peripheral ECS mirror central dysfunctions of endocannabinoid signaling. As a consequence, elements of blood ECS might serve as novel, non-invasive diagnostic tools of several neurological disorders, and targeting the ECS might be useful for therapeutic purposes. In addition, we discuss the appealing working hypothesis that the presence of type-1 cannabinoid receptors on the luminal side, and that of type-2 cannabinoid receptors on the abluminal side of the blood-brain barrier, could drive a unidirectional transport of AEA in the luminal → abluminal direction (i.e., from blood to brain), thus implying that blood may be a reservoir of AEA for the brain. On this basis, it can be expected that an unbalance of the endogenous tone of AEA in the blood may sustain a similar unbalance of its level within the brain, as demonstrated in Huntington's disease, Parkinson's disease, multiple sclerosis, attention-deficit/hyperactivity disorder, schizophrenia, depression and headache.

AB - During immuno-mediated attack of the brain, activation of endocannabinoids represents a protective mechanism, aimed at reducing both neurodegenerative and inflammatory damage through various and partially converging mechanisms that involve neuronal and immune cells. Here, we review the main alterations of the endocannabinoid system (ECS) within the central nervous system and in peripheral blood mononuclear cells, in order to discuss the intriguing observation that elements of the peripheral ECS mirror central dysfunctions of endocannabinoid signaling. As a consequence, elements of blood ECS might serve as novel, non-invasive diagnostic tools of several neurological disorders, and targeting the ECS might be useful for therapeutic purposes. In addition, we discuss the appealing working hypothesis that the presence of type-1 cannabinoid receptors on the luminal side, and that of type-2 cannabinoid receptors on the abluminal side of the blood-brain barrier, could drive a unidirectional transport of AEA in the luminal → abluminal direction (i.e., from blood to brain), thus implying that blood may be a reservoir of AEA for the brain. On this basis, it can be expected that an unbalance of the endogenous tone of AEA in the blood may sustain a similar unbalance of its level within the brain, as demonstrated in Huntington's disease, Parkinson's disease, multiple sclerosis, attention-deficit/hyperactivity disorder, schizophrenia, depression and headache.

KW - Blood-brain barrier

KW - Cannabinoid receptors

KW - Depression

KW - Immune response

KW - Lymphocytes

KW - Metabolism

KW - Migraine

KW - Neurodegeneration

KW - Neuroinflammation

KW - Transport

KW - Vanilloid receptor

UR - http://www.scopus.com/inward/record.url?scp=52949125632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949125632&partnerID=8YFLogxK

U2 - 10.2174/138161208785740018

DO - 10.2174/138161208785740018

M3 - Article

C2 - 18781987

AN - SCOPUS:52949125632

VL - 14

SP - 2370

EP - 2382

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 23

ER -